Candidate*
Indication(s)
Patient population(s)
in vitro
in vivo
IND
Ph1
Ph2
Ph3 Registration
NM002-IV
(Nylexa)
Community Aquired Pneumonia
(CAP)
ICU patients with CAP caused by COVID, flu, bacteria (incl drug resistant bacteria)
- 95%
NM001- oral
(Lynovex)
Pulmonary exacerbations of cystic fibrosis
CF patients experiencing a pulmonary exacerbation of CF requiring IV antibiotic intervention
- 76%
NM001- inhaled
(Lynovex)
Maintenance of ventilatory function in cystic fibrosis
Stable CF patients on standard of care maintenance therapy
- 40%
NP-339-IV*
Invasive mold/yeast
- Cancer patients post IO, chemo
- Stem cell transplant recipients
- 34%
NP339-inhaled
Respiratory fungal disease
- CF patients
- ABPA
- Complex asthma
- NTM
- Lung transplant
- 23%
NP213
Onychomycosis
- Mild-moderate fungal nail disease
- 76%
NP432-IV*
Gram negative bacterial infections/bacteremia
- Patients requiring IV therapy for Gram negative infection/drug resistant infection
- 13%
NP108
A novel strategy for the topical treatment of dermatological conditions NP108 is a peptide antimicrobial specifically designed for topical use in bacterial and polymicrobial dermatological conditions. NP108 is rapidly microbicidal against a number of organisms...
NP432
Targeting a breakthrough against drug resistant bacterial infections NP432 has been derived from a platform of antibacterial peptide therapy candidates. These bactericidal agents have a number of key benefits over conventional antibiotic therapies and the clear...
NP213 (Novexatin)
The first, rapid-acting solution for nail disorders which is based on the nail’s natural defence mechanisms NP213 is a novel peptide, generated from NovaBiotics’ proprietary technology platform. NP213 is based on the natural peptides present within nails and skin and...
NP939
NovaBiotics’ peptide candidate NP339 is in development for the prevention and treatment of life-threatening and life-limiting diseases that can result from compromised immunity Life-threatening fungal infection in immunocompromised patients Patients with compromised...
NM001
Multi-modal symptom-focused therapy for cystic fibrosis (CF) and non-cystic fibrosis bronchiectasis (NCFBE) NM001 is a novel, highly differentiated therapy candidate in development for CF and NCFBE-associated lung disease. NM001 has a unique multi-action including...
NM002
Immunomodulator-antimicrobial for the treatment of inflammatory-infectious disease. NM002 is a small molecule (aminothiol) derived from the innate immune defense response. It has the potential to resolve (hyper)inflammation as well as the infectious cause of that...